| Methods |
Randomised, double‐blind, placebo controlled. Trial conducted in USA |
| Participants |
Ambulatory patients, with mean age 37.5 years, range (21‐50 years). 25% patients were African‐Americans. Male (100%). Baseline mean DBP was 93.3 mmHg. The inclusion criteria was DBP 85‐105 mmHg. Patients were followed for 2 years. Target < 85 mmHg |
| Interventions |
CHTD 50 mg, 100 mg, (53% CHTD alone). Reserpine 0.25 mg. Control: placebo |
| Outcomes |
Mortality, stroke, CHD, CHF, and diastolic BP |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Random sequence generation (selection bias) |
Low risk |
Use of randomization number and subjects were "randomized in double‐blind fashion into active drug therapy and placebo groups". |
| Allocation concealment (selection bias) |
Low risk |
Adequate |
| Blinding (performance bias and detection bias)
All outcomes |
Unclear risk |
Blinding of investigators and patients was achieved. |
| Incomplete outcome data (attrition bias)
All outcomes |
Unclear risk |
Not specified |
| Selective reporting (reporting bias) |
Unclear risk |
Not specified |
